Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 9/20 | 0.36 |
| ▸ | PDE7A | Q13946 | 3/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6521299 | 0.80 | POLB (0.44) | PGRTP53POLBSLC6A2MEN1 | |
| SCHEMBL28225949 | 0.79 | PGR (0.36) | PGRTP53POLBSLC6A2MAPT | |
| SCHEMBL4805389 | 0.79 | SLC6A2 (0.47) | PGRTP53POLBSLC6A2MEN1 | |
| SCHEMBL16324464 | 0.77 | PGR (0.34) | PGRTP53POLBPDE4APDE4B | |
| SCHEMBL28250861 | 0.75 | PGR (0.46) | PGRSLC6A2MAPTMEN1KMT2A | |
| SCHEMBL31383933 | 0.73 | OPRM1 (0.33) | PDE7ATP53MAPT | |
| SCHEMBL28947710 | 0.73 | MAPT (0.35) | PGRPDE7ATP53SLC6A2MAPT | |
| SCHEMBL28141266 | 0.73 | LMNA (0.42) | TP53POLBPDE4APDE4BPDE4C | |
| SCHEMBL31730085 | 0.73 | KDM4E (0.31) | MAPTMEN1KMT2AKDM4ELMNA | |
| SCHEMBL19629948 | 0.72 | PGR (0.41) | PGRPDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143266-B2 | Aryl heterocyclic CGRP receptor antagonists | Merck, Sharp & Dohme Corp (US) | 2012-03-27 | — | — | US | disclosed |
| EP-1794133-B1 | ARYL SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2011-12-14 | — | — | EP | disclosed |
| US-7989624-B2 | Aryl spirolactam CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20100120809-A1 | ARYL HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-05-13 | — | — | US | disclosed |
| EP-2146712-A1 | ARYL HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008130524-A1 | ARYL HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20080004304-A1 | Aryl Spirolactam Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2008-01-03 | — | — | US | disclosed |
| EP-1794133-A2 | ARYL SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006031513-A2 | ARYL SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120809-A1 | ARYL HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | BDKRB1, BDKRB2, CCKBR | PGR 440/4885PDE7A 1279/4885TP53 4846/4885 |
| US-20080004304-A1 | Aryl Spirolactam Cgrp Receptor Antagonists | BDKRB1, BDKRB2, CALCRL | PGR 785/4885PDE7A 1462/4885TP53 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.